BVF
Latest statistics and disclosures from BVF's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MLTX, RVMD, AXSM, PTGX, KYMR, and represent 47.70% of BVF's stock portfolio.
- Added to shares of these 10 stocks: RVMD (+$57M), SNDX (+$41M), ACIU (+$36M), ANNX (+$32M), ETNB (+$25M), ENGN (+$21M), RLAY (+$18M), RPTX (+$15M), SYRE (+$15M), KYMR (+$11M).
- Started 7 new stock positions in SAB Biotherapeutics, ANNX, ENGN, ENGNW, VTGN, SNDX, SYRE.
- Reduced shares in these 10 stocks: IDYA (-$127M), IONS (-$80M), Point Biopharma Global (-$71M), ACRS (-$48M), XENE (-$43M), GPCR (-$38M), REPL (-$37M), AXSM (-$12M), Jasper Therapeutics (-$6.9M), CNTA.
- Sold out of its positions in ACRS, BNOX, IMUX, Jasper Therapeutics, Point Biopharma Global, REPL.
- BVF was a net seller of stock by $-156M.
- BVF has $4.0B in assets under management (AUM), dropping by 7.75%.
- Central Index Key (CIK): 0001056807
Tip: Access up to 7 years of quarterly data
Positions held by BVF consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for BVF
BVF holds 70 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 32.9 | $1.3B | 22M | 60.39 |
|
|
| Revolution Medicines (RVMD) | 4.3 | $172M | +50% | 6.0M | 28.68 |
|
| Axsome Therapeutics (AXSM) | 3.9 | $158M | -7% | 2.0M | 79.59 |
|
| Protagonist Therapeutics (PTGX) | 3.3 | $132M | 5.7M | 22.93 |
|
|
| Kymera Therapeutics (KYMR) | 3.3 | $131M | +8% | 5.2M | 25.46 |
|
| Mirum Pharmaceuticals (MIRM) | 3.2 | $129M | 4.4M | 29.52 |
|
|
| Olema Pharmaceuticals (OLMA) | 3.2 | $128M | 9.1M | 14.03 |
|
|
| Ionis Pharmaceuticals (IONS) | 3.1 | $123M | -39% | 2.4M | 50.59 |
|
| Kura Oncology (KURA) | 2.7 | $106M | +9% | 7.4M | 14.38 |
|
| 4d Molecular Therapeutics In (FDMT) | 2.0 | $81M | 4.0M | 20.26 |
|
|
| Galapagos Nv Spon Adr (GLPG) | 1.9 | $78M | 1.9M | 40.65 |
|
|
| Merus N V (MRUS) | 1.9 | $76M | 2.8M | 27.50 |
|
|
| Repare Therapeutics Ord (RPTX) | 1.9 | $75M | +24% | 10M | 7.30 |
|
| Ac Immune Sa SHS (ACIU) | 1.8 | $73M | +96% | 15M | 5.00 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.7 | $70M | -3% | 8.8M | 7.96 |
|
| Xoma Corp Del Com New (XOMA) | 1.7 | $67M | 3.6M | 18.50 |
|
|
| Ideaya Biosciences (IDYA) | 1.5 | $62M | -67% | 1.7M | 35.58 |
|
| Zymeworks Del (ZYME) | 1.5 | $61M | 5.9M | 10.39 |
|
|
| Gh Research Ordinary Shares (GHRS) | 1.5 | $60M | +12% | 10M | 5.80 |
|
| Essa Pharma Com New (EPIX) | 1.4 | $58M | 8.7M | 6.60 |
|
|
| Janux Therapeutics (JANX) | 1.2 | $49M | 4.6M | 10.73 |
|
|
| Third Harmonic Bio (THRD) | 1.2 | $48M | 4.4M | 10.97 |
|
|
| 89bio (ETNB) | 1.1 | $45M | +119% | 4.0M | 11.17 |
|
| Relay Therapeutics (RLAY) | 1.1 | $44M | +67% | 4.0M | 11.01 |
|
| Xenon Pharmaceuticals (XENE) | 1.0 | $41M | -51% | 890k | 46.06 |
|
| Syndax Pharmaceuticals (SNDX) | 1.0 | $41M | NEW | 1.9M | 21.61 |
|
| Tyra Biosciences (TYRA) | 0.9 | $38M | 2.7M | 13.85 |
|
|
| Lexicon Pharmaceuticals Com New (LXRX) | 0.9 | $37M | +22% | 24M | 1.53 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.8 | $33M | -53% | 813k | 40.76 |
|
| Cullinan Oncology (CGEM) | 0.8 | $33M | 3.2M | 10.19 |
|
|
| An2 Therapeutics (ANTX) | 0.8 | $32M | 1.6M | 20.49 |
|
|
| Annexon (ANNX) | 0.8 | $32M | NEW | 7.0M | 4.54 |
|
| Roivant Sciences SHS (ROIV) | 0.8 | $31M | 2.7M | 11.23 |
|
|
| Silence Therapeutics Ads (SLN) | 0.7 | $26M | 1.5M | 17.37 |
|
|
| Allakos (ALLK) | 0.6 | $23M | 8.6M | 2.73 |
|
|
| Glycomimetics (GLYC) | 0.6 | $23M | 9.5M | 2.36 |
|
|
| Ovid Therapeutics (OVID) | 0.6 | $22M | 6.9M | 3.22 |
|
|
| Engene Holdings (ENGN) | 0.5 | $21M | NEW | 2.3M | 9.23 |
|
| Calliditas Therapeutics Ab Sponsered Ads (CALT) | 0.5 | $19M | 750k | 25.77 |
|
|
| Tscan Therapeutics (TCRX) | 0.4 | $17M | 3.0M | 5.83 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.4 | $17M | 1.5M | 11.17 |
|
|
| Spyre Therapeutics Com New (SYRE) | 0.4 | $15M | NEW | 687k | 21.52 |
|
| Sutro Biopharma (STRO) | 0.4 | $14M | 3.3M | 4.29 |
|
|
| Iteos Therapeutics (ITOS) | 0.3 | $14M | 1.3M | 10.95 |
|
|
| Verastem Com New (VSTM) | 0.3 | $14M | 1.7M | 8.14 |
|
|
| Immunovant (IMVT) | 0.3 | $13M | 300k | 42.13 |
|
|
| Vistagen Therapeutics Ord (VTGN) | 0.3 | $10M | NEW | 2.0M | 5.14 |
|
| Cytomx Therapeutics (CTMX) | 0.3 | $10M | 6.6M | 1.55 |
|
|
| Ikena Oncology (IKNA) | 0.2 | $9.4M | +50% | 4.8M | 1.97 |
|
| Verve Therapeutics (VERV) | 0.2 | $9.1M | 650k | 13.94 |
|
|
| Eledon Pharmaceuticals (ELDN) | 0.2 | $7.8M | 4.3M | 1.80 |
|
|
| SAB Biotherapeutics | 0.2 | $6.3M | NEW | 9.2M | 0.69 |
|
| Vigil Neuroscience (VIGL) | 0.2 | $6.1M | 1.8M | 3.38 |
|
|
| Cidara Therapeutics Inc Common Stock Usd 0.0001 (CDTX) | 0.1 | $5.4M | 6.9M | 0.79 |
|
|
| Rain Therapeutics | 0.1 | $4.2M | 3.5M | 1.20 |
|
|
| Delcath Sys Com New (DCTH) | 0.1 | $4.1M | 976k | 4.16 |
|
|
| Pieris Pharmaceuticals (PIRS) | 0.1 | $3.8M | 21M | 0.18 |
|
|
| Kronos Bio (KRON) | 0.1 | $3.6M | 2.9M | 1.25 |
|
|
| Nls Pharmaceutics SHS (NLSP) | 0.1 | $3.4M | 5.7M | 0.59 |
|
|
| Inventiva Sa Ads (IVA) | 0.1 | $3.1M | 686k | 4.48 |
|
|
| Forte Biosciences (FBRX) | 0.1 | $2.5M | 3.0M | 0.82 |
|
|
| Corvus Pharmaceuticals (CRVS) | 0.1 | $2.4M | 1.4M | 1.76 |
|
|
| Viracta Therapeutics (VIRX) | 0.1 | $2.1M | 3.6M | 0.57 |
|
|
| Molecular Templates Com New (MTEM) | 0.0 | $2.0M | 532k | 3.70 |
|
|
| Unicycive Therapeutics (UNCY) | 0.0 | $1.8M | -37% | 2.1M | 0.87 |
|
| Molecular Partners Ads (MOLN) | 0.0 | $1.8M | 443k | 3.98 |
|
|
| Elevation Oncology (ELEV) | 0.0 | $1.2M | 2.3M | 0.54 |
|
|
| Engene Holdings *w Exp 10/31/202 (ENGNW) | 0.0 | $804k | NEW | 945k | 0.85 |
|
| Aslan Pharmaceuticals Spon Ads New (ASLN) | 0.0 | $548k | 1.0M | 0.52 |
|
|
| Rezolute Com New (RZLT) | 0.0 | $189k | 191k | 0.99 |
|
Past Filings by BVF
SEC 13F filings are viewable for BVF going back to 2010
- BVF 2023 Q4 filed Feb. 14, 2024
- BVF 2023 Q3 filed Nov. 14, 2023
- BVF 2023 Q2 filed Aug. 14, 2023
- BVF 2023 Q1 filed May 15, 2023
- BVF 2022 Q4 filed Feb. 14, 2023
- BVF 2022 Q3 filed Nov. 14, 2022
- BVF 2022 Q2 filed Aug. 15, 2022
- BVF 2022 Q1 filed May 16, 2022
- BVF 2021 Q4 filed Feb. 14, 2022
- BVF 2021 Q3 filed Nov. 15, 2021
- BVF 2021 Q2 filed Aug. 16, 2021
- BVF 2021 Q1 filed May 17, 2021
- BVF 2020 Q4 filed Feb. 12, 2021
- BVF 2020 Q3 filed Nov. 13, 2020
- BVF 2020 Q2 filed Aug. 14, 2020
- BVF 2020 Q1 filed May 15, 2020